Welcome & introduction
Meeting Chairs: Claire Harrison & Amer Zeidan

Session 1: Challenging and uncommon scenarios in MPN (part I)
Chairs: Claire Harrison & Nicola Poleverelli

• Young patients: Marta Sobas
• Pregnancy: TBC
• Skin cancer: Jon Lambert

Panel discussion

Session 2: Challenging and uncommon scenarios in MPN (part II)
Chairs: Andreas Reiter & Deepti Radia

• Transplantation for rare MPN: Nicola Poleverelli
• Management of eosinophilia: Andreas Reiter
• Mastocytosis indolent: Deepti Radia

Panel discussion

Break

Session 3: Novel approaches to upfront management of MF (part I)
Chairs: Alessandro Vannucchi & TBC

• Classification and risk stratification: Alessandro Vannucchi
• When should a low-risk patient be treated and with what?: TBC
• What is a suboptimal responder?: Stephen Oh

Panel discussion

Session 4: Novel approaches to upfront management of MF (part II)
Chairs: Prithviraj Bose & Kathrin Haifa Al Ali

• Selinexor: TBC
• Updates on JAK inhibitors & JAKi-naïve studies: Prithviraj Bose
• Pelabresib: John Mascarenas
• Navetamadlin: Kathrin Haifa Al Ali

Panel discussion

Lunch

Session 5: Updates on new therapies (part I)
Chairs: Jan Bewersdorf & Firas El Chaer

• Interferon: Jan Bewersdorf
• Imetelstat: John Mascarenhas
• Nuvisertib: Firas El Chaer
• Elritercept: Claire Harrison

Panel discussion

Session 6: Updates on new therapies (part II)
Chairs: Bethan Psaila & Shahram Kordasti

• CALR: Bethan Psaila
• Updates with hepicidin targets in PV: Marina Kremenskaya
• Type 2 or mutation specific JAKi: David Steensma
• Targeting inflammation: Shahram Kordasti

Panel discussion

 

Break

Session 7: Novel thoughts on blastic phase and transplantation
Chairs: Adam Mead & Donal McLornan

• Diagnosis and risk stratification of AP and BP: Adam Mead
• What do we know about the biology of blast phase MPN? TBC
• Options for management of accelerated and blast phase: Should they be treated in the same way and how should we incorporate BMT? Donal McLornan
• Transplant for MF: Juan Carlos Hernández-Boluda

Panel discussion

Day 1 wrap up
Claire Harrison

Welcome to Day 2
Amer Zeidan

Keynote talk 1
Immunome in prognostication and immune interventions management in MDS: Shahram Kordasti

Session 8: MDS classification and risk stratification
Chairs: TBC & TBC

• Molecular classification of MDS: Robert Hasserjian
• Roadmap for harmonization of classifications in MDS: The icMDS recommendations: Luca Lanino
• Consistent eligibility criteria for MDS clinical trials – the icMDS recommendations: Uma Borate
• AI in classification and risk stratification of MDS: Adrián Mosquera Orgueira

Panel discussion

Break

Session 9: Translational advances in MDS
Chairs: TBC & TBC

• Epigenetic targeting MDS: Francesc Sole
• Clonal evolution in MDS: TBC
• Spatial multi-omics in myeloid cancers: TBC
• Talk title TBC (cardio-oncology): Alexander Lyon

Panel discussion

Session 10: Defining response criteria in MDS
Chairs: TBC & TBC                                 

• An update on response assessment in MDS: Lisa Pleyer
• Debate: MRD should be an endpoint in the assessment of MDS
  • Yes: Arjan Van De Loosdrecht
  • No: Michael Savona
• Should CR be achieved before alloBMT for HR-MDS? Max Stahl

Panel discussion

Lunch

Session 11: Targeting mutations in MDS
Chairs: TBC & TBC                                                                                                  

• Epigenetic targeting of MDS: Klaus Metzeler
• How should TP53-mutated MDS be classified?: Matteo Della Porta
• TP53-mutated MDS targeting – New directions: Thomas Cluzeau
• DDX41-mutated MDS/AML: Carmelo Gurnari

Panel discussion

Session 12: Novel pathways and therapeutic targets in MDS
Chairs: TBC & TBC

• Updates on the biology of telomerase inhibition in MDS: Valeria Santini
• Is there a pathway forward for RARA agonists in MDS?: Amy DeZern
• Updates on PK agonist use in MDS: Amer Zeidan
• Updates on TGF pathway modulation in MDS: Hetty Carraway

Panel discussion

Break

Session 13: iwMDS 2025: Recognition awards
Chairs: Amer Zeidan & Valeria Santini      

• Introduction: TBC
• Recipient presentation 1 (title TBC): TBC
• Recipient presentation 2 (title TBC): TBC

Session 14: Title TBC
Chairs: TBC & TBC

• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC

Panel discussion

Day 2 wrap up
Amer Zeidan

Welcome to Day 3
Amer Zeidan

Keynote talk 2
Updates on QoL assessment in MDS: the icMDS recommendations: Fabio Efficace

Session 15: Evolving strategies in the management of lower-risk MDS
Chairs: Eva Hellström-Lindberg & TBC    

• How to define disease modification in LR-MDS: Rami Komrokji
• What do we know about luspatercept + ESA combinations for LR-MDS? Lionel Ades
• How do I sequence imetelstat in MDS?: Mikkael Sekeres
• Standardized reporting of MDS clinical trials – The icMDS recommendations: TBC

Panel discussion

 

Session 16: Advancements in targeted therapies and immunomodulation in MDS
Chairs: TBC & TBC          

• IRAK inhibitors in MDS – What’s next?: Anne Sophie Kaubasch
• An update on immune checkpoint use in MDS/AML: Amer Zeidan
• Venetoclax in MDS: Yazan Madanat
• IDH inhibitors for MDS: Marie Sebert
• An update on oral hypomethylating agents in MDS – what’s next?: Elizabeth Griffiths

Panel discussion

Break

Session 17: Controversies in current therapies for HR-MDS
Chairs: TBC & TBC   

• Debate: What is the optimal management strategy for MDS-IB2?
  • HMA/Ven: Lionel Ades
  • HMA monotherapy: TBC

Panel discussion

Session 18: Controversies in transplant for MDS
Chairs: TBC & TBC

• Debate: TP53 HR-MDS – Should you transplant or not?
  • Transplant: Coleman Lindsley
  • No transplant: Alain Mina
• Recommendations for transplant for MDS in 2025: Carmelo Gurnari

Panel discussion

Session 19: Global perspectives on MDS trials
Chairs: TBC & TBC          

• MDS trials in China: Bing Li
• MDS trials in Japan: Yasushi Miyazaki
• MDS trials in Germany: Katharina Götze
• MDS trials in France: Lionel Ades
• MDS trials in Italy: Valeria Santini
• MDS trials in Spain: María Díez-Campelo

Panel discussion

Meeting summary and close
Claire Harrison & Amer Zeidan